Multi-year, 1143-patient genetic study identified unique types of multiple myeloma
On Aug. 19, 2024, an international team of scientists led by researchers from the Translational Genomics Research Institute (TGen) announced…
Lilly opened state-of-the-art research and development center in the Boston Seaport
On Aug. 13, 2024, Eli Lilly announced the opening of the Lilly Seaport Innovation Center (LSC), a research…
BioNTech sued by UPenn over COVID-19 vaccine patent royalties
On Aug. 6, 2024, the University of Pennsylvania announced it had sued German biotechnology firm BioNTech n Pennsylvania…
Biotechnology | Influenza | Vaccine | WHO
New initiative launched to advance mRNA vaccine development against human avian influenza (H5N1)
On Jul. 29, 2024, a new project that aims to accelerate the development and accessibility of human avian…
Twist Bioscience Launched Synthetic RNA Control for H5N1 Influenza A
On Jul. 9, 2024, Twist Bioscience announced the expansion of its growing portfolio of synthetic viral controls with…
Moderna Received $176 million Award through BARDA to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
On Jul. 2, 2024, Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle…
FDA Permited Marketing of First Point-of-Care Hepatitis C RNA Test
On Jun. 27, 2024, the U.S. Food and Drug Administration granted marketing authorization to Cepheid for the Xpert…
Biotechnology | Influenza | Therapeutics | USDA | Vaccine | Veterinary
USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
On Jun. 25, 2024, Merck Animal Health announced U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine…
Houston Zoo Elephant Received First Ever mRNA EEHV Vaccine
On Jun. 18, 2024, the Houston Zoo announced that Tess, a 40-year-old Asian elephant at the Zoo, had…
CSL Seqirus Signed an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU
On Jun. 11, 2024, CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part…
$140 million for UBC-led research hub to accelerate drug development and biomanufacturing
On May 31, 2024, a national research coalition led by the University of British Columbia (UBC) announced a…
Moderna received U.S. FDA approval for RSV vaccine mRESVIA
On May 31, 2024, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mRESVIA (mRNA-1345),…
Moderna announced contract with Brazil to supply 12.5 million COVID-19 vaccines as part of national vaccination campaign
On Apr. 22, 2024, Moderna announced a contract with the Ministry of Health in Brazil (Ministerio da Saude)…
Vaccine breakthrough means no more chasing strains
On Apr. 15, 2024, scientists at University of California Riverside demonstrated a new, RNA-based vaccine strategy that is…
Novavax’s protein-based non-mRNA COVID-19 vaccine available as additional dose for individuals aged 65 and older
On Feb. 28, 2024, the U.S. Centers for Disease Control and Preventionﾒs (CDC) Advisory Committee on Immunization Practices…
COVID-19 vaccination and boosting during pregnancy protects infants for six months
On Feb. 14, 2024, the National Institute of Allergy and Infectious Diseases (NIAID) reported study results that showed…
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…
Abnormal proteins found in the spinal fluid of people with ALS and frontotemporal dementia
On Jan. 31, 2024, researchers at the National Institutes of Health detected abnormal proteins in the spinal fluid…
Biotechnology | Diagnostics | Disease | NIH | Therapeutics | Women's Health
NIH-supported researchers created single-cell atlas of the placenta during term labor
On Jan. 10, 2024, an National Institutes of Health (NIH) supported study announced an n atlas revealing the…
CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
BioNTech aimed to start mRNA vaccine output in Rwanda in 2025
On Dec. 18, 2023, COVID-19 vaccine maker BioNTech (22UAy.DE) announced that it aims to start production at its…
Biotechnology | Diagnostics | Disease | Genomics | Neurology | Therapeutics
Alberta researchers revealed full structure of ‘ancient genetic parasite’ implicated in human diseases
On Dec. 14, 2023, the University of Alberta announced that a study published in Nature sheds light on…
BioNTech and Australiaﾒs State of Victoria signed agreement on strategic partnership to strengthen mRNA rcosystem
On Dec. 7, 2023, BioNTech announced that it had signed a multi-year strategic partnership with the State of…
Japan’s MHLW approved CSL and Arcturus’s self-amplifying mRNA vaccine approved for COVID in adults
On Nov. 28, 2023, CSL and Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare (MHLW)…
Novavax’s prototype COVID-19 vaccine Nuvaxovid received full approval in Singapore
On Oct. 18, 2023, Novavax announced that Singapore’s Health Sciences Authority (HSA) had granted full approval for Novavax’s…
FDA authorized updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variant
On Oct. 3, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
COVID-19 | CRISPR | Therapeutics | Vaccine
Nobel Prize in medicine was jointly awarded to Katalin Kariko and Drew Weissman “for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19”
On Oct. 2, 2023, the Nobel Prize in Physiology or medicine was awarded jointly to Katalin Kariko and…
Pfizer and BioNTech received Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
On Sept. 28, 2023, Pfizer and BioNTech that Health Canada had authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19…
Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19
On Sept. 27, 2023, Gritstone bio announced that it was awarded a contract by the Biomedical Advanced Research…
Pfizer and BioNTech received U.S. FDA approval for 2023-2024 COVID-19 vaccine
On Sept. 11, 2023, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…